Σάββατο 20 Αυγούστου 2011

CANCER PREVENTION-DOGS CAN PROBABLY HELP!!!

August 17, 2011 — German researchers say that highly trained dogs are able to reliably sniff out lung cancer in human breath.
In its early stages, lung cancer has few symptoms, making it difficult for doctors to catch it early, when it's still treatable.
"This is the holy grail," says Suresh S. Ramalingam, MD, associate professor and director of the lung program at Emory University's Winship Cancer Institute in Atlanta.
"The whole field is focused on using something that's readily available that does not involve an expensive surgery or scan that would allow us to find early cancers," says Ramalingam, who is developing technology that aims to replicate the ability of dogs to smell trace amount of chemicals produced by cancerous tumors. He was not involved in the research.
Recently a large, government-funded study found that longtime smokers at high risk for lung cancer who received annual rapid computed tomography (CT) scans of their lungs cut their risk of dying of the disease by 20%.
But that test has caused controversy because it falsely detects cancer in about one out of four people, leading to further invasive procedures.
Checking for Lung Cancer
The new study, which is published in the European Respiratory Journal, found that four trained dogs -- two German shepherds, an Australian shepherd, and a Labrador retriever -- correctly identified cancer in 71 of 100 samples from lung cancer patients.
They also ruled out cancer in 372 out of 400 samples that were known not to have cancer, giving them a very low rate of false positives, about 7%.
"The surprising result of our study is the very high specificity of our dogs to identify lung cancer," says study researcher Thorsten Walles, MD, a lung surgeon at Schillerhoehe Hospital in Gerlingen, Germany.
"It even surpasses the combination of chest computed tomography (CT) scan and bronchoscopy, which is an invasive procedure that needs some form of anesthesia," Walles tells WebMD in an email.
Doctors have previously reported cases in which dogs have alerted their owners to undiagnosed skin, breast, and lung cancers by repeatedly pawing or nosing an affected body part. Some dogs have even been trained to smell low blood sugar levels in people who have diabetes.
But dogs have had more mixed success in carefully controlled studies, where samples from healthy people and sick people have been mixed.
A study published in BMJ in 2004 found that dogs correctly identified bladder cancer an average of about 40% of the time, a rate that was better than the 14% accuracy that could be expected by chance, but was lower than available tests.
But in June, researchers in Japan reported that dogs could detect the presence of colon cancer in human breath and stool samples with nearly 90% accuracy, a success rate only slightly lower than colonoscopy.
The length of time the dogs are trained may be an important difference between the studies, Walles says. In his study, the four dogs were trained for nine months. Other studies have used dogs trained for as little as three weeks.
The kind of sample the dogs are asked to smell -- urine, breath, blood, or stool -- may also influence the results, he says.
In his study, 220 volunteers -- 110 who were healthy, 60 who had lung cancer, and 50 with chronic obstructive pulmonary disease (COPD) -- were asked to exhale into a glass tube filled with fleece.
The tubes were mixed up so neither the dogs' handlers nor two observers who placed the samples on the floor in front of the dogs knew the status of the person they were from, to avoid inadvertently giving the dogs clues about what they should find.
The dogs were presented with five tubes at a time. Only one contained a sample from a person with cancer.
The dogs were trained to lie down and put their nose to the tube if they detected lung cancer.
The dogs appeared to be able to accurately identify the samples from cancer patients, even when they were in very early stages of the disease. And they were able to pick up the scent despite competing odors of cigarette smoke or food on a person's breath.

How Dogs Detect Cancer

Researchers think dogs and other animals are able to smell disease by picking up on minute changes in compounds called volatile organic compounds (VOCs) that comprise chemical signatures in the body.
As many as 4,000 different VOCs, for example, have been identified in human breath.
A dog's sense of smell has been estimated to be 100 to 1,000 times more powerful than a human's, says Gary K. Beauchamp, PhD, director of the Monell Chemical Senses Center in Philadelphia.
"It's not just how sensitive their nose is. It's how they process this into a recognition pattern," Beauchamp says. "The reason dogs can do this is that they're recognizing a complex picture, and that's the big trick, to find out how to mimic that in some sort of device that could be useful for diagnostic purposes in human disease."
Other researchers agree.
Ramalingam says because success rates vary between dogs and between samples, the real value of knowing dogs can detect cancer will likely be in building technology that can reliably repeat what they can do.
"The dogs show that it can be done. We need to find out what the dogs are sniffing so we can do it in a more scientific manner."

VITAMIN D IMROVES PAIN FROM AROMATASE INHIBITORS

August 16, 2011 — High-dose vitamin D supplementation significantly improves musculoskeletal pain and discomfort caused by aromatase inhibitors (AIs) and may have a positive effect on bone health, according to a single-center, phase 2 study reported in the August issue of Breast Cancer Research and Treatment.
Musculoskeletal pain occurs in up to 50% of patients taking the drugs and is reportedly the most common reason for AI discontinuation, say the study authors, led by Antonella Rastelli, MD, from Washington University School of Medicine in St. Louis, Missouri.
"Women usually report that 'every bone in my body hurts' and that, since starting AIs, they feel like they 'have become 100 years old,'" they write.
In the new study of 60 patients with breast cancer who had been receiving the AI anastrozole (Arimidex, AstraZeneca) for at least 2 months, all the women took the recommended daily dose of vitamin D2 — 400 IU — plus 1000 mg of calcium a day.
For the study, patients randomly assigned to treatment received an additional high dose of vitamin D2 (50,000 IU capsule), which was given once a week; pain was measured at baseline and at 8-week intervals for up to 6 months.
At 8 weeks, pain scores were better for patients randomly assigned to high-dose vitamin D2 than for those assigned to placebo. The scores with significant improvement included pain measured by the Fibromyalgia Impact Questionnaire (P = .0045) and the Brief Pain Inventory-Short Form (BPI), which included BPI worst pain (P = .04), BPI average pain (P = .0067), BPI pain severity (P = .04), and BPI interference (P = .034).
The positive effect of high-dose vitamin D supplementation was not maintained at 4 and 6 months once the women were switched to a less frequent dose (50,000 IU once a month), as required by the study protocol.
"The apparent decline in efficacy may reflect the relatively short half-life and weak potency of Vitamin D2," write the authors about the once-monthly dose.
The study is the first randomized trial to assess the efficacy of high-dose vitamin D supplementation in women with breast cancer taking AIs. Two previous observational studies have "reported a potential role of vitamin D" for reducing musculoskeletal pain in this setting, say the authors.
It is uncertain how exactly vitamin D is helpful in these patients. "The pathogenesis of aromatase inhibitor-induced musculoskeletal symptoms and why it may respond to vitamin D is unclear," say the authors.
However, there is a "prevalence of vitamin D insufficiency or deficiency in women with breast cancer despite standard supplementation (e.g. oral vitamin D2; 400 IU/day)," the authors point out. And "clinical observation" — along with the 2 observational studies — has suggested that high-dose vitamin D may ameliorate musculoskeletal pain, they add.
Bone Impact Too
At enrollment, study participants had hormone receptor–positive invasive breast cancer (stage I to IIIB) and, after taking an AI for 2 months, were experiencing new or worsening musculoskeletal pain unrelated to any history of trauma. Other eligibility criteria included serum 25OHD level between 10 and 29 ng/mL, which is a range that covers both "insufficient" and "deficient" vitamin D levels.
A secondary goal of the study was to assess the efficacy of high-dose vitamin D supplementation in protecting bone health in patients with breast cancer receiving AI therapy.
"It is well known that AIs cause bone loss and are associated with an increased risk of fragility fractures," write the authors. Also, vitamin D deficiency/insufficiency is a risk factor for bone loss through the development of secondary hyperparathyroidism, they add, suggesting that this is a one-two punch on bone health for women in the study.
The investigators found that women taking placebo showed a decline in bone mineral density (BMD) of the femoral neck at 6 months (mean change, –1.4% ± 0.68%), while women receiving vitamin D supplementation maintained BMD (0.35% ± 0.72%; P = .06). No significant changes were observed at the lumbar spine or total femur.
"The favorable effect of vitamin D on BMD at the femoral neck potentially reflects increased mineralization of bone matrix from improved calcium absorption," they write.
One of the adverse effects of high-dose vitamin D supplementation came into play in the study.
There was a "relatively high dropout rate due to hypercalciuria." At 8 weeks, 5 patients (4 in the vitamin D group and 1 in the placebo group) developed abnormally high 24-hour urinary calcium excretion, which underscores the importance of monitoring patients taking high-dose vitamin D for this abnormality, advise the authors.
The study was supported by AstraZeneca. The authors have disclosed no relevant financial relationships.
Breast Cancer Res Treat. 2011;129:107-116. Abstract

VEMURAFENIB APPROVED BY FDA

August 17, 2011 — The US Food and Drug Administration (FDA) today approved the oral targeted therapy vemurafenib (Zelboraf, Plexxikon/Roche) for the first-line treatment of both metastatic and unresectable melanomas.
The drug is specifically indicated for patients with melanoma whose tumors have V600E mutations in the BRAF gene. An estimated 50% of patients with melanoma have this type of BRAF mutation, which does not occur in normal cells. The drug is not indicated for use in patients without the mutation.
Vemurafenib is a BRAF inhibitor that blocks the function of the V600E-mutated BRAF protein.
Vemurafenib has been approved with a companion diagnostic test that will help determine whether a patient's melanoma cells have the BRAF V600E mutation. The first-of-a-kind test is known as the cobas 4800 BRAF V600 Mutation Test (Roche Molecular Systems).
"This has been an important year for patients with late-stage melanoma. Zelboraf is the second new cancer drug approved that demonstrates an improvement in overall survival," said Richard Pazdur, MD, director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research, in a press statement. "In March, we approved Yervoy (ipilimumab), another new treatment for late-stage melanoma that also showed patients live longer after receiving the drug."
Ipilimumab (Bristol-Myers Squibb) is an immunotherapy also indicated for the treatment of metastatic and unresectable melanoma. Vemurafenib will be marketed differently, as it targets a more specific patient population.
"Today's approval of Zelboraf and the cobas test is a great example of how companion diagnostics can be developed and used to ensure patients are exposed to highly effective, more personalized therapies in a safe manner," said Alberto Gutierrez, PhD, director of the Office of In Vitro Diagnostic Device Evaluation and Safety in the FDA's Center for Devices and Radiological Health.
The FDA's approval of the cobas 4800 BRAF V600 Mutation Test was based on data from the same study that evaluated the safety and effectiveness of vemurafenib.
Vemurafenib was reviewed under the FDA's priority review program that provides for an expedited 6-month review of drugs that may offer major advances in treatment or that provide a treatment when no adequate therapy exists, says the agency.
Vemurafenib will be marketed in the United States by Genentech and Daiichi Sankyo; rights for the drug were transferred to Daiichi Sankyo when the company acquired Plexxikon, which discovered vemurafenib and codeveloped this new medicine with Roche.
Pivotal Study Details
In a recently presented phase 3 trial, vemurafenib improved progression-free and overall survival, compared with standard chemotherapy, in patients with advanced melanoma with no previous treatment.
Patients receiving vemurafenib had a 74% reduction in the risk for progression (or death), compared with patients receiving dacarbazine chemotherapy (hazard ratio, 0.26; P < .001). Mean progression-free survival was 5.3 months in the vemurafenib group, compared with 1.6 months in the dacarbazine group.
The progression-free survival data constitute "an unprecedented level of difference," said lead author Paul Chapman, MD, from Memorial Sloan-Kettering Cancer Center in New York City, who presented the data at the American Society of Clinical Oncology (ASCO) annual meeting earlier this year, as reported by Medscape Medical News.
At 6 months, estimated overall survival was 84% (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group. No median overall survival was reported because the data are not mature enough, Dr. Chapman said at ASCO. The study was published in June in the New England Journal of Medicine (2011;364:2507-2516).
In that interim analysis, the median follow-up of the overall survival data was 3.8 months in the vemurafenib group and 2.3 months in the dacarbazine group.
Response rates were 48% for vemurafenib and 5% for dacarbazine (P < .001) in that study, which is known as the BRAF Inhibitor in Melanoma (BRIM)-3 study.
After reviewing the interim analysis, an independent data and safety monitoring board recommended that patients receiving dacarbazine cross over to vemurafenib.
Resistance and Combinations
The complete response rate seen so far with the new drug has been low — just 2 of the 219 patients (0.9%) receiving vemurafenib whose tumor response was evaluated in the pivotal study.
Vemurafenib is also subject to drug resistance, a problem acknowledged by Plexxikon officials.
"Tumor regrowth occurs in many of the patients," wrote a pair of Plexxikon researchers in a 2010 study about resistance.
A partial solution to this problem might be to combine targeted therapies for melanoma, said a number of experts at the ASCO meeting this year.
A phase 1 trial has already begun with vemurafenib and ipilimumab, reported Dr. Chapman at that meeting.
In addition, a phase 1 study presented there indicated that combining 2 oral targeted therapies, the MEK inhibitor GSK212 and the BRAF inhibitor GSK436, was safe and had preliminary antitumor activity in patients with advanced melanoma.
Adverse Events
In the pivotal BRIM-3 trial, which was conducted at 104 centers in 12 countries, participants had previously untreated, inoperable stage IIIc or IV metastatic melanoma and a V600E mutation in the BRAF gene. Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg/m2 of body-surface area intravenously every 3 weeks).
Common adverse events associated with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma, squamous cell carcinoma, photosensitivity, nausea, and diarrhea. Notably, 38% of patients required a dose modification because of toxic effects.
Less than 10% of patients who received vemurafenib experienced problems with high levels of toxicity (grade 3 or worse). The most common of these high-grade adverse effects were skin rashes, photosensitivity, and joint pain.
The investigators also reported that 12% of patients in the vemurafenib group developed grade 3 or worse cutaneous squamous cell carcinoma, compared with less than 1% in the dacarbazine group.
The BRIM-3 study was sponsored by Hoffman-La Roche. Dr. Chapman reports serving as a consultant/advisor for and receiving research funding from Roche. Other coauthors report financial relationships with industry, including Roche, or are employees of Roche.

ANNUAL PAP TEST NOT ALWAYS NECESSARY

August 18, 2011 — A representative survey of nearly 600 US physicians concludes that the majority continue to recommend annual cervical cancer screening, even for women whom current guidelines say can wait 3 years before being tested again.
Results from the survey were published online today in the American Journal of Obstetrics & Gynecology.
"Our findings suggest a need for continued surveillance and data collection on adherence to cervical screening guidelines, and perhaps an open dialogue on provider, patient, and systems preferences for prevention and management of cervical cancer and abnormalities," write Katherine Roland, MPH, from the Epidemiology and Applied Research Branch, Division of Cancer Prevention and Control, Centers for Disease Control, and colleagues.
"Appropriate use of cervical cancer screening technologies is essential, now more than ever, if [human papillomavirus (HPV)] co-testing is to be considered a preventive service for women covered by insurance providers," states Ms. Roland in a press release.
The researchers point out that current guidelines published by the American Cancer Society and the American College of Obstetricians and Gynecologists recommend that for women 30 years of age or older, providers use a combination of 2 tests to screen for cervical cancer: the Papanicolaou test and the HPV cotest.
If the results of the 2 tests come back normal, recommendations say the women can wait 3 years before being retested.
However, the results of the current survey indicate that most providers are not following those recommendations.
Roland and colleagues analyzed data on HPV testing and cotesting practices captured in 2006 by the CDC's Cervical Cancer Screening Supplement. The screening supplement is administered as part of the CDC's National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey. The data included responses from 376 physicians based in private practice and 216 physicians who worked in hospital outpatient departments.
As part of the survey, physicians who ordered HPV cotests were asked about what sorts of retesting recommendations they would make in 3 types of hypothetical clinical situations. Each situation involved a woman between 30 and 60 years of age with a current normal Papanicolaou test status. The 3 scenarios were as follows:
  • the patient has no current HPV test results and a history of 2 consecutive normal Papanicolaou tests,
  • the patient has a current negative HPV test result and a history of 2 consecutive normal Papanicolaou tests, and
  • the patient has a current negative HPV test result and has never had a Papanicolaou test.
Current guidelines recommend that women in all 3 of those clinical situations be advised they can wait 3 years before returning for retesting.
Even so, the researchers found that for scenario 1, 76.4% of office-based providers (95% confidence interval [CI], 69.3% - 82.3%) and 85.2% of hospital-based providers (95% CI, 72.6% - 92.6%) would recommend the patient be rescreened in 12 months.
For scenario 2, 66.6% of office-based providers (95% CI, 59.1% - 73.4%) and 72.7% of hospital-based providers (95% CI, 57.8% - 83.8%) would recommend a follow-up Papanicolaou test in 12 months.
Notably, the authors write, only 14% of office-based providers (95% CI, 9.2% - 20.6%) would recommend the next Papanicolaou test in 3 or more years, as the current guidelines recommend.
In the case of scenario 3, 73.4% of office-based providers (95% CI, 63.3% - 81.5%) and 73.5% of hospital-based providers (95% CI, 63.1% - 81.8%) would recommend a follow-up Papanicolaou test in 12 months.
The researchers say a large percentage of office-based providers (25.2%; 95% CI, 17.8% - 34.4%) and hospital-based providers (24.9%; 95% CI, 16.6% - 35.6%) would recommend the next Papanicolaou test be scheduled within a 12-month period.
Study limitations include a large percentage of survey completion by "other office staff" and small sample size, which led to a large variance in response to the descriptive clinical vignettes.
Commenting on their findings, the researchers say that establishing patients' history of normal Papanicolaou test results appears to be a critical component to providers making guideline-supported recommendations regarding screening intervals.
"Approximately one-half of providers ordered the HPV co-test for their patients; of those providers, approximately two-thirds ordered the test for women ≥30 years old, which is the only approved use of the HPV co-test," they write.
They conclude: "Understanding discordance between clinical policy and practice, which can result in unnecessary testing costs and burden to the women, should be central to future research initiatives."
The authors have disclosed no relevant financial relationships.
Am J Obstet Gynecol. Published online August 18, 2011.

AZACITIDINE EFFECTIVE AGAINST AML

NEW YORK (Reuters Health) Aug 11 - Azacitidine effectively treats acute myeloid leukemia (AML) in nearly a third of patients, researchers from Italy report in the July 14th online Cancer.
"In elderly (>70 yrs) patients with AML, the main goal of therapy is to prolong survival, maintaining a good quality of life (e.g., no mucositis, ability to perform outpatient therapy, etc)," Dr. Luca Maurillo from Tor Vergata Foundation Polyclinic, Rome, told Reuters Health in an email. "Demethylating agents seem to be promising drugs for this purpose."
Dr. Maurillo and colleagues investigated the efficacy of azacitidine in a retrospective analysis of 82 patients with AML who received azacitidine between June 2005 and December 2009.
Thirty-five patients were treatment na�ve and 47 patients had received other chemotherapy before they were treated with azacitidine.
The overall response rate was 32%, including 12 complete remissions (15%), 4 complete remissions with incomplete blood count recovery (5%), and 10 partial remissions (12%).
The response rate was higher among previously untreated patients (17/35, 48%) than among pretreated patients (9/47, 19%).
The median overall survival from start of azacitidine treatment was 9 months in previously untreated patients and 7 months in previously treated patients. At a median follow-up of 12 months, the projected overall survival was 35% in the untreated group and 18% in the pretreated group.
The lack of prior treatment and white blood cell counts below 10 billion/L were significantly associated with a response to azacitidine, whereas white blood cell count was the only factor significantly associated with overall survival duration.
Just over a quarter of the patients (22/82, 27%) experienced grade 3 or 4 myelosuppression, 9 patients (11%) developed febrile neutropenia, and 10 patients (12%) developed infection. Eleven patients (13%), including 4 untreated and 7 pretreated, died during treatment.
"It would be certainly interesting to compare in a randomized trial azacitidine with supportive care (mainly in patients >70 years) or other chemotherapy drugs to confirm the real benefit of the drug," Dr. Maurillo said. "In this regard, there is an ongoing international trial that will clarify this open question."
"The therapeutic results of classic chemotherapy in elderly patients with AML are strongly limited by toxic deaths," Dr. Maurillo added. "New drugs less toxic than chemo, such as cloretazine, are being tested with results comparable to demethylating agents."
Azacitidine isn't currently FDA-approved for use in AML, but formal clinical trials are underway. Azacitidine is FDA-approved for several myelodysplastic syndrome (MDS) subtypes, including refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).

SNPs PREDICTING AGGRESIVE PROSTATE CANCER

August 19, 2011 — Prostate cancer is the second leading cause of cancer-related deaths in men, but one of the challenges in this disease has been the inability to differentiate between men who have aggressive tumors and those who have indolent tumors that might never become clinically significant.
However, researchers have now identified 5 genetic variants that are strongly associated with aggressive, lethal prostate cancer.
Published online August 16 in Cancer Epidemiology, Biomarkers and Prevention, this is the first population-based study to demonstrate that germline genetic variants provide prognostic information for prostate cancer-specific survival.
"It is really promising as we now have identified inherited genetic variants that provide prognostic information for prostate cancer," said lead study author Janet L. Stanford, PhD, codirector of the Program in Prostate Cancer Research at the Fred Hutchinson Cancer Research Center in Seattle, Washington.
She told Medscape Medical News that they hoped that this panel of markers, along with others that may be identified in the future, "can help complement the existing clinical and pathological features of prostate cancer to better stratify patients according to the likelihood of having a more aggressive type of prostate cancer."
The Five SNPs
In this study, 5 single-nucleotide polymorphisms (SNPs) were validated as being significantly associated with prostate cancer–specific mortality (P ≤ .05). The 5 SNPs were located, one each, in the following 5 genes:
  • LEPR, the strongest marker associated with prostate cancer mortality in the study, is a cytokine receptor that is highly expressed in normal and malignant prostate tissue. The binding of leptin to its receptor leads to several downstream effects that may affect prostate carcinogenesis, including stimulation of tissue growth, inflammation, angiogenesis, and bone mass regulation. The latter effect, note the study authors, makes LEPR an interesting candidate for disease progression because the primary metastatic site for prostate cancer is the bone and bony metastases are predictive of fatal prostate cancer;
  • CRY1, the cryptochrome 1 gene, is in the circadian rhythm pathway, and circadian clock genes regulate androgen levels, which are known to affect prostate cancer progression and may also function as tumor suppressors through regulation of cell proliferation, apoptosis, and response to DNA damage;
  • RNASEL is associated with hereditary prostate cancer and is associated with apoptosis, inflammation, and cell proliferation and adhesion;
  • IL4 plays a role in cancer via activation of the Stat6 transcription factor; and
  • ARVCF is a member of the p120 catenin family of proteins, and increased expression has been shown to disrupt cell adhesion, which may facilitate cancer progression.
Patients with 4 to 5 at-risk genotypes had a 50% higher risk for prostate cancer–specific mortality than patients who had only 2 or fewer of these genotypes. After adjusting for clinicopathological factors know to affect prognosis, the risk for mortality increased with the number of at-risk genotypes (P for trend = .001).
Results Too Early
Similar to other malignant tumors, prostate cancer is a complex disease that results from an interaction between genetic and nongenetic factors. As previously reported by Medscape Medical News, a number of studies have identified genetic variants that may be associated with prostate cancer risk or more aggressive disease.
In one of those previous studies, Rosalind Eeles, MA, PhD, FRCP, FRCR, head of the Cancer Genetics Unit, Royal Marsden NHS Foundation Trust, in Surrey, United Kingdom, and colleagues, identified 7 loci that were significantly associated with prostate cancer on chromosomes 3, 6, 7, 10, 11, 19, and X and confirmed reports of common loci associated with prostate cancer at 8q24 and 17q.
Commenting on her work at that time, Dr. Eeles emphasized that it was still too early to consider marketing genetic tests to the public, and further research was needed. When approached for independent commentary about the current study, she felt that it was also too soon to draw conclusions.
"It is too early to say if this study will be useful as it needs validation, and this is in progress," she told Medscape Medical News.
Study Details
Dr. Stanford and colleagues analyzed DNA in blood samples obtained from 1309 prostate cancer patients residing in the Seattle area. A total of 937 SNPs were genotyped from this cohort, and a total of 22 SNPs were found to be significantly associated with prostate cancer–specific mortality.
The 22 top ranking SNPs identified in the Seattle cohort were then genotyped in the validation cohort, which consisted of 2875 prostate cancer patients in Sweden. From the validation study, 5 of the 22 SNPs emerged as being significantly associated with death from prostate cancer. As compared to patients with 0 to 2 at-risk genotypes, those with all 5 SNP genotypes had the lowest prostate cancer–specific survival in both the Seattle (P < .001) and the Swedish (P = .004) cohorts.
On the basis of models that were adjusted for age at diagnosis and other clinicopathological variables, the most significant SNP in the Seattle dataset was rs1137100 (P = .001) in the LEPR gene and in the Swedish dataset was rs10778534 (P = .045) in the CRY1 gene.
The study authors also observed that a higher proportion of Swedish patients (17.4%) had died of prostate cancer relative to those from Seattle (4.6%) during a median follow-up period of 6.5 years. These data are consistent with the higher prostate cancer mortality rate in Sweden relative to the United States, they point out.
Further Validation Studies Needed
"We completed a validation study of the 22 SNPs that were identified as associated with prostate cancer mortality in our Seattle-based cohort and validated that 5 of those SNPs were also associated with prostate cancer mortality in the Swedish cohort," explained Dr. Stanford. "So the 5 individual SNPs are already validated."
They now hope to complete additional validation studies using the 22 SNPs and then undertake studies to validate the panel of 5 SNPs, along with any others that may be validated from the panel of 22, she added. "The published results represent the initial step in moving forward for finding and confirming that a patient's genetic background plays a role in determining the course of their prostate cancer."
As for the implications for clinical practice, she pointed out that a blood test to measure these SNPs would not be difficult to develop. "But we need to wait until further validation studies are completed before we will know how useful this panel of SNPs will be in complimenting Gleason score, stage, and PSA [prostate-specific antigen] for guiding decisions in the clinic," she said. "This initial study, however, provides the first validated evidence that a patient's inherited genetic background can affect prostate cancer aggressiveness and thereby outcomes."
The study was funded by grants from the National Institutes of Health, the Fred Hutchinson Cancer Research Center, the Intramural Program of the National Human Genome Research Institute, the Cancer Risk Prediction Center, a Linneus Centre (contract 70867902) financed by the Swedish Research Council, the Swedish Research Council, the Swedish Cancer Foundation, the Hedlund Foundation, the Söderberg Foundation, the Enqvist Foundation, and ALF funds from the Stockholm County Council.
Cancer Epidemiol Biomarkers Prev. Published online August 16, 2011.

POTENTIAL USE OF IMATINIB IN BENIGN BONE TUMMORS

NEW YORK (Reuters Health) Aug 15 - While very toxic, imatinib may prove useful for treating two rare, usually benign neoplasms, namely, pigmented villonodular synovitis (PVNS) and tenosynovial giant cell tumors (TGCT), according to a report online August 5th in Cancer.
Patients with PVNS and TGCT, which are different clinical presentations of the same disease, commonly over-express colony-stimulating factor 1 (CSF1). Imatinib mesylate is a tyrosine kinase inhibitor that has activity against CSF1 receptor (CSF1R).
Dr. Philippe A. Cassier from Leon Berard Center, Lyon, France and colleagues tested imatinib in 29 patients with PVNS/TGCT. All but one received 400 mg imatinib daily.
The mean age was 41 years. The median follow-up for all patients was 10.8 months.
Fifteen patients discontinued treatment, six of them because of treatment-related side effects.
One patient (4%) had a complete response, four (15%) had partial responses, and 20 (74%) had stable disease, for an overall response rate of 19% and a symptomatic response rate (reduction of pain and/or swelling) of 73%.
Six patients had progressed as of the last follow-up (including three with progression at the first assessment).
All but one patient was still alive at the last follow-up.
"Imatinib may represent an alternative to radiotherapy for patients who have symptomatic TCGT/PVNS that progresses or that is not amenable to surgery," the researchers conclude.
"The benefits of alleviating morbidity in patients with localized PVNS/TGCT must be balanced against the potential toxicity of chronic drug therapy," they add.
"Furthermore," the investigators say, "although our data provide proof of concept for targeting CSF1/CSF1R in TGCT/PVNS, formal studies are needed to confirm the role of imatinib mesylate in this disease. Two international phase II trials using nilotinib, a CSF1R tyrosine kinase inhibitor with potency similar to that of imatinib mesylate, in patients with advanced TGCT or PVNS are currently ongoing."

CRBOPLATIN-CAELYX AS FIRST LINE TREATMENT IN OVARIAN CANCER

J Clin Oncol. 2011 Aug 15. [Epub ahead of print]

Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial.

Pignata S, Scambia G, Ferrandina G, Savarese A, Sorio R, Breda E, Gebbia V, Musso P, Frigerio L, Del Medico P, Lombardi AV, Febbraro A, Scollo P, Ferro A, Tamberi S, Brandes A, Ravaioli A, Valerio MR, Aitini E, Natale D, Scaltriti L, Greggi S, Pisano C, Lorusso D, Salutari V, Legge F, Di Maio M, Morabito A, Gallo C, Perrone F.

Abstract

PURPOSE Carboplatin/paclitaxel is the standard first-line chemotherapy for patients with advanced ovarian cancer. Multicentre Italian Trials in Ovarian Cancer-2 (MITO-2), an academic multicenter phase III trial, tested whether carboplatin/pegylated liposomal doxorubicin (PLD) was more effective than standard chemotherapy. PATIENTS AND METHODS Chemotherapy-naive patients with stage IC to IV ovarian cancer (age ≤ 75 years; Eastern Cooperative Oncology Group performance status ≤ 2) were randomly assigned to carboplatin area under the curve (AUC) 5 plus paclitaxel 175 mg/m(2) or to carboplatin AUC 5 plus PLD 30 mg/m(2), every 3 weeks for six cycles. Primary end point was progression-free survival (PFS). With 632 events in 820 enrolled patients, the study would have 80% power to detect a 0.80 hazard ratio (HR) of PFS. Results Eight hundred twenty patients were randomly assigned. Disease stages III and IV were prevalent. Occurrence of PFS events substantially slowed before obtaining the planned number. Therefore, in concert with the Independent Data Monitoring Committee, final analysis was performed with 556 events, after a median follow-up of 40 months. Median PFS times were 19.0 and 16.8 months with carboplatin/PLD and carboplatin/paclitaxel, respectively (HR, 0.95; 95% CI, 0.81 to 1.13; P = .58). Median overall survival times were 61.6 and 53.2 months with carboplatin/PLD and carboplatin/paclitaxel, respectively (HR, 0.89; 95% CI, 0.72 to 1.12; P = .32). Carboplatin/PLD produced a similar response rate but different toxicity (less neurotoxicity and alopecia but more hematologic adverse effects). There was no relevant difference in global quality of life after three and six cycles. CONCLUSION Carboplatin/PLD was not superior to carboplatin/paclitaxel, which remains the standard first-line chemotherapy for advanced ovarian cancer. However, given the observed CIs and the different toxicity, carboplatin/PLD could be considered an alternative to standard therapy.

PREDICTIVE FACTORS OF SECOND LINE CHEMOTHERAPY IN UROTHELIAL CANCER

Eur Urol. 2011 Aug 4. [Epub ahead of print]

Prognostic Factors in Second-Line Treatment of Urothelial Cancers With Gemcitabine and Paclitaxel (German Association of Urological Oncology Trial AB20/99).

Niegisch G, Fimmers R, Siener R, Park SI, Albers P; for the German Association of Urological Oncology Bladder Cancer Group.

Source

Department of Urology, Heinrich Heine University, Medical Faculty, Düsseldorf, Germany.

Abstract

BACKGROUND:

In the treatment of urothelial cancer, identification of patients who are likely to benefit from further therapy after cisplatin failure is crucial for reasonable treatment decisions.

OBJECTIVE:

Validate the prognostic factor model (PFM) for survival developed by Bellmunt et al. in a different patient cohort with a different chemotherapy regimen.

DESIGN, SETTING, AND PARTICIPANTS:

Baseline parameters of 102 patients treated within a randomized phase 3 trial of second-line gemcitabine and paclitaxel (GP) comparing short-term to prolonged chemotherapy (German Association of Urological Oncology trial AB20/99) were analyzed. Patients were stratified according to the PFM based on a score including performance status, presence of hepatic metastases, and hemoglobin levels.

MEASUREMENTS:

The baseline parameters of the GP cohort were compared with those of patients treated in the phase 3 trial of vinflunine versus best supportive care. Univariate and multivariate analyses of baseline parameters with respect to overall survival (OS) and treatment response were performed. OS of patients stratified according to the PFM was compared by log-rank test.

RESULTS AND LIMITATIONS:

The vinflunine and the GP cohorts differed, as patients after perioperative (neoadjuvant or adjuvant) treatment were included in the latter cohort. According to the PFM, prognostic subgroups with significant difference in OS (11.8 mo [95% confidence interval (CI), 6.3-17.3], 8.1 mo [95% CI, 4.8-11.4], 3.2 mo [95% CI, 0.0-7.9]; p=0.007) were identified. The PFM identified risk groups in patients with failed treatment of metastatic disease (14.1 mo [95% CI, 8.9-19.3], 7.3 mo [95% CI, 0.0-17.8], 3.8 mo [95% CI, 0.0-9.0]; p=0.006) but not in patients treated (neo)adjuvantly. Lymph node-only disease was a strong predictor of treatment response that overruled every other single predictive parameter (0.284, p=0.0266).

CONCLUSIONS:

The PFM was successfully validated in the GP and should be used to tailor second-line treatment strategy. Patients with lymph node-only disease may benefit from second-line treatment even if anemia or impaired performance status is present.

POEMS SYNDROME

Am J Hematol. 2011 Jul;86(7):591-601. doi: 10.1002/ajh.22050.

POEMS syndrome: 2011 update on diagnosis, risk-stratification, and management.

Dispenzieri A.

Source

Laboratory Medicine and Pathology, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA. dispenzieri.angela@mayo.edu

Abstract

DISEASE OVERVIEW: POEMS syndrome is a paraneoplastic syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyradiculoneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease. Minor features include organomegaly, endocrinopathy, characteristic skin changes, papilledema, extravascular volume overload, and thrombocytosis. Diagnoses are often delayed because the syndrome is rare and can be mistaken for other neurologic disorders, most commonly chronic inflammatory demyelinating polyradiculoneuropathy. POEMS syndrome should be distinguished from the Castleman disease variant of POEMS syndrome, which has no clonal PCD and typically little to no peripheral neuropathy but has several of the minor diagnostic criteria for POEMS syndrome. DIAGNOSIS: The diagnosis of POEMS syndrome is made with three of the major criteria, two of which must include polyradiculoneuropathy and clonal plasma cell disorder, and at least one of the minor criteria. RISK STRATIFICATION: Because the pathogenesis of the syndrome is not well understood, risk stratification is limited to clinical phenotype rather than specific molecular markers. The number of clinical criteria is not prognostic, but the extent of the plasma cell disorder is. Those patients with an iliac crest bone marrow biopsy that does not reveal a plasma cell clone are candidates for local radiation therapy; those with a more extensive or disseminated clone will be candidates for systemic therapy. RISK-ADAPTED THERAPY: For those patients with a dominant sclerotic plasmacytoma, first line therapy is irradiation. Patients with diffuse sclerotic lesions or disseminated bone marrow involvement and for those who have progression of their disease 3 to 6 months after completing radiation therapy should receive systemic therapy. Corticosteroids are temporizing, but alkylators are the mainstay of treatment, either in the form of low dose conventional therapy or high dose with stem cell transplantation. The benefit of anti-VEGF antibodies is conflicting. Lenalidomide shows promise with manageable toxicity. Thalidomide and bortezomib also have activity, but their benefit needs to be weighed against their risk of exacerbating the peripheral neuropathy. Prompt recognition and institution of both supportive care measures and therapy directed against the plasma cell result in the best outcomes.

AVASTIN IN GASTRIC CANCER-ANOTHER FAILURE

J Clin Oncol. 2011 Aug 15. [Epub ahead of print]

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study.

Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK

Abstract

PURPOSE The Avastin in Gastric Cancer (AVAGAST) trial was a multinational, randomized, placebo-controlled trial designed to evaluate the efficacy of adding bevacizumab to capecitabine-cisplatin in the first-line treatment of advanced gastric cancer. PATIENTS AND METHODS Patients received bevacizumab 7.5 mg/kg or placebo followed by cisplatin 80 mg/m(2) on day 1 plus capecitabine 1,000 mg/m(2) twice daily for 14 days every 3 weeks. Fluorouracil was permitted in patients unable to take oral medications. Cisplatin was given for six cycles; capecitabine and bevacizumab were administered until disease progression or unacceptable toxicity. The primary end point was overall survival (OS). Log-rank test was used to test the OS difference. Results In all, 774 patients were enrolled; 387 were assigned to each treatment group (intention-to-treat population), and 517 deaths were observed. Median OS was 12.1 months with bevacizumab plus fluoropyrimidine-cisplatin and 10.1 months with placebo plus fluoropyrimidine-cisplatin (hazard ratio 0.87; 95% CI, 0.73 to 1.03; P = .1002). Both median progression-free survival (6.7 v 5.3 months; hazard ratio, 0.80; 95% CI, 0.68 to 0.93; P = .0037) and overall response rate (46.0% v 37.4%; P = .0315) were significantly improved with bevacizumab versus placebo. Preplanned subgroup analyses revealed regional differences in efficacy outcomes. The most common grade 3 to 5 adverse events were neutropenia (35%, bevacizumab plus fluoropyrimidine-cisplatin; 37%, placebo plus fluoropyrimidine-cisplatin), anemia (10% v 14%), and decreased appetite (8% v 11%). No new bevacizumab-related safety signals were identified. CONCLUSION Although AVAGAST did not reach its primary objective, adding bevacizumab to chemotherapy was associated with significant increases in progression-free survival and overall response rate in the first-line treatment of advanced gastric cancer.

RESISTANCE TO ABIRATERONE

Clin Cancer Res. 2011 Aug 1. [Epub ahead of print]

Resistance to CYP17A1 inhibition with abiraterone in castration resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants.

Mostaghel EA, Marck B, Plymate S, Vessella RL, Balk SP, Matsumoto AM, Nelson PS, Montgomery B.

Source

Clinical Research Division, Fred Hutchinson Cancer Research Center.

Abstract

PURPOSE:

Abiraterone is a potent inhibitor of the steroidogenic enzyme CYP17A1 and suppresses tumor growth in patients with castration-resistant prostate cancer (CRPC). The effectiveness of abiraterone in reducing tumor androgens is not known, nor have mechanisms contributing to abiraterone resistance been established.

EXPERIMENTAL DESIGN:

We treated human CRPC xenografts with abiraterone and measured tumor growth, tissue androgens, androgen receptor (AR) levels, and steroidogenic gene expression vs. controls.

RESULTS:

Abiraterone suppressed serum PSA levels and improved survival in two distinct CRPC xenografts: median survival of LuCaP35CR improved from 17 to 39 days (HR 3.6, p=0.0014) and LuCaP23CR from 14 to 24 days (HR 2.5, p=0.0048). Abiraterone strongly suppressed tumor androgens, with testosterone (T) decreasing from 0.49 + 0.05 to 0.07 + 0.04 pg/mg (p<0.0001), and from 0.69 + 0.11 to 0.22 + 0.08 pg/mg (p=0.002) in abirater-one-treated 23CR and 35CR, respectively, with comparable decreases in tissue DHT. Treatment was associated with increased expression of full length AR (ARFL) and trun-cated AR variants (ARFL 2.3 fold, p=0.008 and ARdel567es 2.7 fold, p=0.036 in 23CR; ARFL 3.4 fold, p=0.001 and ARV7 3.1 fold, p=0.0003 in 35CR), and increased expression of the abiraterone target CYP17A1 (~2.1 fold, p=0.0001and p=0.028 in 23CR and 35CR, respectively) and transcript changes in other enzymes modulating steroid metabolism.

CONCLUSIONS:

These studies indicate that abiraterone reduces CRPC growth via suppression of intratumoral androgens and that resistance to abiraterone may occur through mechanisms that include upregulation of CYP17A1, and/or induction of AR and AR splice variants that confer ligand-independent AR transactivation.

Τρίτη 16 Αυγούστου 2011

TAXANES MAY BE LESS EFFECTIVE IN BRCA1+ ER- PATIENTS

NEW YORK (Reuters Health) Aug 12 - Taxanes are less effective in some patients with BRCA1 mutations, according to Dutch investigators.
If confirmed, the results "can have a major impact on the choice of type of (adjuvant) chemotherapy in BRCA1 mutation carriers with hormone receptor negative or triple negative breast cancer," said lead author Dr. Mieke Kriege in email to Reuters Health.
In a July 14th online paper in Cancer, Dr. Kriege and colleagues at Erasmus MC-Daniel den Hoed Cancer Center in Rotterdam note there is growing evidence from preclinical studies that sensitivity to taxanes requires a functional BRCA1 protein.
The present study, they write, "confirms the preclinical data, however, only for BRCA1-associated patients with hormone receptor (HRec)-negative and not HRec-positive breast cancer."
The researchers studied 48 patients who had received either docetaxel (Taxotere) or paclitaxel (Taxol) for metastatic breast cancer, including 35 BRCA1 carriers and 13 BRCA2 carriers. They also analyzed 95 matched controls with sporadic metastatic breast cancer.
Compared to the control group, the BRCA1 carriers had fewer objective responses (23% vs. 38%), more progressive disease (60% vs. 19%) and a shorter median progression-free survival (2.2 vs. 4.9 months).
In the subgroup of HRec-negative patients, objective response rates were 20% in BRCA1 patients and 42% in patients with sporadic disease. Seventy percent of HRec-negative BRCA carriers had disease progression, vs. 26% of controls. The mutation carriers also had a shorter progression-free survival: 1.8 vs. 3.8 months.
In the HRec-positive patients, however, outcomes were similar in BRCA1 carriers and controls.
In BRCA2-associated patients, who were mainly HRec-positive, the objective response was higher than in sporadic patients (89% vs. 38%).
If the results can be replicated, Dr. Kriege said, HRec-negative BRCA carriers might be better off with an anthracycline- or platinum-containing regimen instead of taxane chemotherapy, "which is nowadays a cornerstone in most of the adjuvant chemotherapeutic regimens."

Κυριακή 14 Αυγούστου 2011

A BREAKTHROUGH DISCOVERY-GENETICALLY MODIFIED T CELLS CAN CURE CLL

August 10, 2011 — Although the data are preliminary, a novel technique shows promise as a potent and sustained method of cancer immunotherapy. Autologous T cells expressing an anti-CD19 chimeric antigen receptor (CART19) produced a rapid and long-lasting response in patients with refractory chronic lymphocytic leukemia (CLL).
In a case report published online August 10 in the New England Journal of Medicine, a patient with advanced P53-deficient CLL received a CART19 cell infusion, and on day 23, there was no evidence of CLL in the bone marrow.
Computed tomography (CT) scans performed 3 months after the procedure showed sustained remission, and bone marrow studies at 3 and 6 months showed no evidence of CLL. "The patient remains in remission 1 year after his infusions," explained first author David L. Porter, MD, professor of medicine and director of blood and marrow transplantation at the Hospital of the University of Pennsylvania, Philadelphia.
"He is fully recovered from any and all side effects, has no symptoms, and is fully functional," he told Medscape Medical News.
A second patient who experienced a complete response after CART19 infusions also remains in remission 1 year after therapy. "The third patient had a dramatic but partial response," said Dr. Porter. "He has relatively stable disease."
Gene transfer techniques have been developed to genetically modify T cells to stably express antibodies on their surface, conferring new antigen specificity, note the authors. Chimeric antigen receptors combine an antigen-recognition domain of a specific antibody with an intracellular domain of the CD3-zeta chain or FcγRI protein into a single chimeric protein. The authors report that including the CD137 (4-1BB) signaling domain in preclinical models significantly increased antitumor activity, along with "in vivo persistence of chimeric antigen receptors," compared with the CD3-zeta chain alone.
The authors point out that in the majority of malignancies, tumor-specific antigens are not well defined. However, that is not the case in B cell cancers, in which CD19 is a potential target, because the expression of CD19 is restricted to normal and malignant B cells and their precursors.
Even though this study is preliminary, it has tremendous potential for patients with CLL, non-Hodgkin's lymphoma, and possibly lymphoblastic leukemia (ALL), explained Dr. Porter.
"All express CD19," he said. "The only curative therapy for patients with CLL has been allogeneic SCT [stem cell transplantation], at the expense of extensive morbidity and mortality. If this therapy is effective long-term, it would have the potential to replace the need for allogeneic SCT."
"In addition, many patients are too old, have other medical problems, or don't have a suitable donor, all making allogeneic SCT impractical," he added. "Furthermore, these results show that this technology can be tremendously potent, which has broad implications for other diseases. Similar vectors can be designed to target other molecules on other tumor types."
Dr. Porter and his colleagues are planning to continue this trial in a small number of patients to better assess initial and long-term responses and toxicity. "We hope to study this therapy earlier in the course of the disease, potentially making it safer and even more effective," he said. "We plan to extend these studies to patients with other CD19-expressing malignancies, such as non-Hodgkin's lymphoma and ALL. In addition, with this powerful example of 'proof of principle,' we hope to apply this technology to patients with other malignancies."
Needs Widespread Use
In an accompanying editorial, Walter J. Urba, MD, PhD, and Dan L. Longo, MD, note that the "expansion, persistence, and development of the memory phenotype, not to mention antitumor effects, of these T cells were impressive."
Dr. Urba, from the Providence Cancer Center in Portland, Oregon, and Dr. Longo, a deputy editor at the New England Journal of Medicine, caution that toxicity could become more of a problem as more potent second- and third-generation chimeric antigen receptors are used in patients with varying tumor types. Safety measures include infusing a lower number of T cells, using immunosuppressive agents, and the "introduction of a 'suicide signal' to kill cells when they are creating mischief."
"Only with more widespread clinical use of chimeric antigen-receptor T cells will we learn whether the results reported by Porter et al. reflect an authentic advance toward a clinically applicable and effective therapy or yet another promising lead that runs into a barrier that cannot be easily overcome," they conclude.
Case Study
In this pilot study, the authors treated 3 patients with advanced CLL with autologous T cells expressing CART19, and reported on the immunologic and clinical efficacy in 1 patient.
That patient was diagnosed with stage I CLL in 1996, and first required treatment 6 years later. He was treated with rituximab plus fludarabine in 2002, which resulted in normalization of his blood counts and partial regression of his adenopathy. The patient received further treatment in 2006, and was disease-free for 20 months.
In February 2009, the patient experienced rapidly progressive leukocytosis and recurrent adenopathy, and CLL was observed in his bone marrow. Cytogenetic testing revealed a deletion of chromosome 17p in 3 of 15 cells, and fluorescence in situ hybridization (FISH) testing showed that 170 of 200 cells had a deletion involving TP53 on chromosome 17p. Patients with TP53 deletions tend to have short remissions after standard therapies, the authors note.
Autologous T cells were collected from the patient in December 2009 and cryopreserved. He then received alemtuzumab for 11 weeks. This resulted in improved hematopoiesis and partially resolved adenopathy. During the next 6 months, the patient experienced stable disease with persistent and extensive bone marrow involvement and diffuse adenopathy. In July 2010, he was enrolled in a phase 1 clinical trial of chimeric antigen-receptor-modified T cells.
Pentostatin and cyclophosphamide were administered to deplete the lymphocytes; 4 days later, the patient received 1.42 ₓ 107 transduced T cells. The unselected T cells were infected with a self-inactivating lentiviral vector, designed by the authors to carry genes for the chimeric antigen receptor. No postinfusion cytokines were administered, and there were no toxic effects related to the infusion.
The patient began experiencing chills and a low-grade fever associated with grade 2 fatigue 14 days after the infusion. Symptoms escalated during the next 5 days, and tumor lysis syndrome was diagnosed on day 22. The patient was subsequently hospitalized, treated with fluids and rasburicase, and discharged 4 days later.
On day 28, the karyotype was normal in 15 of 15 cells, and FISH testing was negative for deletion TP53 in 198 of the 200 cells that were examined. This is considered to be within normal limits in negative control subjects, the authors note.
At 3 and 6 months after the infusion, the patient's physical exam remained unremarkable. There was no palpable adenopathy, CT scanning showed sustained remission, and bone marrow studies revealed no evidence of CLL on morphologic analysis, karyotype analysis (46,XY), or flow cytometric analysis.
N Engl J Med. Published online August 10, 2011. Abstract, Editorial

HIGH DOSE CHEMOTHERAPY FOR GERM CELL TUMORS

Expert Rev Anticancer Ther. 2011 Jul;11(7):1093-105.

High-dose chemotherapy and stem cell transplantation for advanced testicular cancer.

Voss MH, Feldman DR, Motzer RJ.

Source

Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, NY 10065, USA.

Abstract

High-dose chemotherapy (HDCT) with autologous stem cell support has been studied in both the salvage and first-line setting in advanced germ cell tumor (GCT) patients with poor-risk features. While early studies reported significant treatment-related mortality, introduction of peripheral blood stem cell transplantation, recombinant growth factors and better supportive care have decreased toxicity; and in more recent reports treatment-related deaths are observed in <3% of patients. Two to three cycles of high-dose carboplatin and etoposide is the standard backbone for HDCT, given with or without additional agents including ifosfamide, cyclophosphamide and paclitaxel. Three large randomized Phase III trials have failed to show a benefit of HDCT over conventional-dose chemotherapy (CDCT) in the first-line treatment of patients with intermediate- or poor-risk advanced GCT, and to date the routine use of HDCT has been reserved for the salvage setting. Several prognostic models have been developed to help predict outcome of salvage HDCT, the most recent of which applies to both CDCT and HDCT in the initial salvage setting. Patients that relapse after HDCT are usually considered incurable, and additional therapy is provided with palliative intent.

SENTINEL NODE BIOPSY EFFECTIVE IN HEAD-NECK MELANOMAS

Sentinel node biopsy safe and effective in head and neck melanomas

09.08.11
Category: Scientific News

New study refutes controversy about technique in delicate head and neck region


Sentinel node biopsy, a common technique for determining whether melanoma has spread can be used safely and effectively even in tumors from the head and neck area, according to a new study from the University of Michigan Comprehensive Cancer Center.

Many surgeons believed that the complex anatomy combined with the critical nerves and blood vessels in the head and neck area made sentinel lymph node biopsy unsafe and inaccurate for melanomas in that region.

In the study, which appears online in Cancer, researchers looked at 353 head and neck melanoma patients who had received sentinel lymph node biopsy at University of Michigan Comprehensive Cancer Center over a 10-year period. After reviewing patients' records, the researchers found that the sentinel lymph node could be identified in all, and no patients sustained permanent nerve injuries during the procedure.

About 20% of the patients had at least one sentinel node positive for cancer and were referred for a complete dissection to remove additional lymph nodes. Among the remaining 283 patients with negative sentinel nodes, 12 patients recurred in the region where the sentinel lymph node was identified. This suggests that the test yielded 12 false-negative results, which means a negative test was incorrect 4% of the time. This rate is similar when sentinel lymph node biopsy is used for melanomas in other parts of the body.

According to Dr Carol Bradford, the author of the study and professor and chair of otolaryngology at the University of Michigan Medical School, sentinel lymph node biopsy is a safe and effective way to determine the status of the regional nodal basin for melanomas affecting the head and neck region. Furthermore, the study showed that it can be done accurately in these patients.

The researchers also found that sentinel lymph node biopsy was the biggest predictor of how well a patient would do after surgery, including overall survival as well as recurrence-free survival. They concluded that the procedure should be offered in patients with head and neck melanomas the same as to patients with melanomas in other parts of the body. Sentinel lymph node biopsy is feasible and safe in these patients, and it helps determine the best course of treatment.

The Multidisciplinary Melanoma Clinic at the University of Michigan Comprehensive Cancer Center includes specialty surgeons highly skilled in performing this procedure.

E2A LOSS IMPORTANT IN SEZARY SYNDROME

Genomic loss of putative tumor suppressor gene E2A is crucial for a rare Sézary syndrome

08.08.11
Category: Scientific News

Fundamentally new insights into genesis and development of Sézary syndrome and possibly other human lymphomas


Scientists in Germany have succeeded in providing fundamentally new insights into the genesis and development of Sézary syndrome, which is largely unexplained to date. The malignant Sézary syndrome origin is a CD4+ T-lymphocyte from peripheral blood. Epidermotropism by neoplastic CD+ lymphocytes with the formation of Pautrier's microabscesses is the hallmark sign of the disease. In contrast to most other skin lymphomas, patients with Sézary syndrome manifest not only skin contamination but also presence of degenerate T-cells in the peripheral blood and lymph nodes even at the onset of the disease.

German researchers investigated highly purified tumor cells from patients with Sézary syndrome using array comparative genomic hybridization technique for hitherto unknown genetic changes. In doing so they identified areas in the genotype of these tumor cells that have become lost in many of the patients examined. A detailed analysis of these areas showed that one of the most frequently affected genes codes for a transcription factor. Transcription factors have key functions in the regulation of cellular gene activity.

According to Chalid Assaf from the Charité Klinik für Dermatologie, Venerologie und Allergologie the partial loss of the gene for transcription factor E2A appears to play an essential role in this context because the gene is normally of great importance for natural lymphocyte development. In mice a loss of this gene leads to the genesis of aggressive T cell lymphomas. However, a gene loss in one of the various human lymphoma classes had so far remained elusive.

The researchers also identified several E2A-regulated genes and signal paths in tumor cells, the mere deregulation of each of which is sufficient to enable a tumor to develop. Stephan Mathas, a scientist at the Charité Klinik für Hämatologie und Onkologie emphasized that the loss of E2A in Sézary syndrome is of crucial importance for the aggressive behavior of tumor cells because it contributes to more rapid, uncontrolled growth of cells. Consequently, it was directly proven for the first time that E2A in humans has the function of a tumor suppressor.

German researchers hope that these findings will lead to the development of new, more effective treatment concepts for patients with Sézary syndrome.

The study was supported by the 7th EU Framework Programme, Deutsche Forschungsgemeinschaft, Berliner Krebsgesellschaft, and Max Planck Innovation Fonds.

c-KIT IN MELANOMA

c-KIT: A therapeutic target in metastatic melanoma

04.08.11
Category: Scientific News

Imatinib shows efficacy in melanoma patients enriched for KIT mutations or amplifications


In patients diagnosed with metastatic melanoma, recently approved antibody ipilimumab and the small molecule vemurafenib have shown to improve overall survival over previous standards of care, but there are melanoma subtypes for which they are not effective. Therefore, research for alternative therapies is ongoing.

An open-label phase II study, published in the JAMA, has recently sought to identify the subtype of patients with melanoma who might respond best to the multi-kinase inhibitor imatinib mesylate. According to Dr Richard Carvajal, first author of the study, a subset of melanomas is characterized by activating alterations in the gene coding for the kinase KIT, and his team assessed whether KIT inhibition in this subset could impact melanomas progression.

Out of 295 cases of melanoma enrolled into the study, 51 patients were identified to have KIT mutations or amplifications. These cases were from a cohort of patients with melanoma subtypes previously shown to be enriched for these types of genetic alterations (from acral, musocal and chronically sun-damaged sites). The identified patients were offered treatment with imatinib and 28 patients went on to receive the therapy. In two patients durable complete responses were achieved, in two durable partial responses and in five stable disease that lasted for at least 12 weeks (two of these lasting for more than 6 months).

This study serves as an important proof of concept that inhibition of the protein KIT in patients with advanced melanoma that are biologically driven by activating mutations in KIT can lead to significant clinical benefit. Importantly, not all mutations in KIT had the same responses. All six of the durable responses were observed in patients with L576P or K642E amino acid substitutions, which are the most common KIT alterations in melanoma.

The study shows how is important to understand the molecular biology behind driver mutations prior to using them for patient selection in clinical trials. In previous trials, in which the patients were not selected based on activating mutations in KIT, no evidence of imatinib efficacy was observed. It is needed to further refine how to select patients for imatinib therapy and investigate other agents or combinations of agents.

DOCETAXEL-VINORELBINE COMBINATION

Breast Cancer Res Treat. 2011 Aug 9. [Epub ahead of print]

SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer.

Livingston RB, Barlow WE, Kash JJ, Albain KS, Gralow JR, Lew DL, Flaherty LE, Royce ME, Hortobagyi GN.

Source

Arizona Cancer Center, Hematology/Oncology Section, 1515 N Campbell Avenue, PO Box 245024, Tucson, AZ, 85724-5024, USA, living@azcc.arizona.edu.

Abstract

SWOG trial S0102 showed significant activity of the combination of docetaxel and vinorelbine in HER2-negative metastatic breast cancer (MBC). For HER2-positive patients, additional benefit may occur with the addition of trastuzumab due to its synergy with docetaxel and vinorelbine. Patients with HER2-positive MBC, but without prior chemotherapy for MBC or adjuvant taxane, were eligible. Docetaxel (60 mg/m(2)) was given intravenously on Day 1, vinorelbine (27.5 mg/m(2)) intravenously on Days 8 and 15, and filgrastim (5 µg/kg) on Days 2-21 of a 21-day cycle. In addition, patients received weekly infusions of trastuzumab (2 mg/kg) after an initial bolus of 4 mg/kg. The primary outcome was 1 year overall survival (OS), with secondary outcomes of progression-free survival (PFS), response rate, and toxicity. Due to slow accrual (February 2003-December 2006), enrollment was stopped after 76 of 90 planned patients. There have been 32 deaths and 51 progressions among the 74 eligible patients who received treatment. The estimated 1 year OS was 93% (95% CI 84-97%) with a median of 48 months. One-year PFS was 70% (95% CI 58-79%) with a median of 20 months. Response rate for measurable disease was 84%. No deaths were attributed to treatment. Grade 4 toxicities were reported for 19% with neutropenia the most common (15%). The most common grade 3 toxicities (33%) were leucopenia (14%) and fatigue (10%). The combination of trastuzumab, docetaxel, and vinorelbine is effective as first-line chemotherapy in HER2-positive MBC with minimal toxicity. One-year survival estimates are among the highest reported in this population.

A RARE ADVERSE EVENT

Clin Cancer Res. 2011 Aug 3. [Epub ahead of print]

Thrombotic Microangiopathy with Targeted Cancer Agents.

Blake-Haskins JA, Lechleider RJ, Kreitman RJ.

Source

Clinical Development, MedImmune, LLC.

Abstract

Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are clinically similar disorders characterized by microvascular thrombosis, hemolysis, thrombocytopenia, and end organ damage. Although they may present with overlapping symptoms, multiple etiologies have been proposed for these thrombotic microangiopathies (TMAs). Chemotherapy-induced TMA has been described with the use of mitomycin, gemcitabine, and others and has a poor prognosis. Recently, reports of TMA associated with targeted cancer agents have surfaced in the literature. We discuss the clinical presentation, outcome, and etiology of TMA reported with the use of immunotoxins, monoclonal antibodies, and tyrosine kinase inhibitors. A search of PubMed and meeting abstracts was conducted for cases of TMA with the use of targeted cancer agents. The defining symptoms, laboratory values, time to onset, and patient outcomes were compiled. Consistent definitions of TMA and grading of severity in these cases are lacking. However, presentation of TMA in these cases revealed the importance of monitoring for renal toxicity, hemolysis, and thrombocytopenia. Patient outcomes appear to differ from those seen in cases of chemotherapy-induced TMA and may reflect a different underlying etiology. Little is known about the pathogenesis of TMA with targeted cancer agents. In contrast to chemotherapy-induced TMA, partial to full reversibility may be a common outcome. However, further research is warranted into optimal management of patients diagnosed with TMA following treatment with targeted agents.

FOLFOX MAY BE SAFE IN PREGNANCY

Clin Colorectal Cancer. 2011 Jul 29. [Epub ahead of print]

Successful Twin Pregnancy Outcome After In Utero Exposure to FOLFOX for Metastatic Colon Cancer: A Case Report and Review of the Literature.

Jeppesen JB, Osterlind K.

Source

Department of Clinical Physiology and Nuclear Medicine, Hvidovre Hospital, Hvidovre, Denmark; Department of Oncology, Rigshospitalet, Copenhagen, Denmark.

Abstract

There is limited experience in treating advanced colorectal cancer diagnosed during pregnancy because it is a rare occurrence; however, the incidence of colorectal cancer complicating pregnancy is expected to increase in the future. The combination of cancer and pregnancy is complicated and causes many dilemmas and concerns for the physician and patient. A delay in treatment may compromise maternal survival; however, therapy for the cancer may be harmful to the fetus. We present a case of a 26-year-old woman pregnant with twins who was diagnosed with metastatic colon cancer and treated with 5-fluorouracil, leukovorin, and oxaliplatin (FOLFOX) from 13 weeks gestational age to birth. The patient gave birth to healthy twins without malformations at 33 weeks gestational age. At follow-up examination, the 2-year-old twins are developing normally. The patient herself died 1 year after the initial cancer diagnosis. This shows a case in which the administration of FOLFOX during the second and third trimester of pregnancy caused no fetal harm. These findings are similar to those of previous studies in which systemic chemotherapy administered during the second and third trimester was relatively safe. However, we know that chemotherapy should be avoided during the first trimester.

ONCE DAILY TRIPLE HIV DRUG APPROVED

August 10, 2011 — The US Food and Drug Administration (FDA) today granted approval of Complera, a once-daily, 3-drug combination for treatment-naive HIV-infected patients.
Complera is a single tablet that contains rilpivirine (Edurant, Janssen Pharmaceuticals), a nonnucleoside reverse transcriptase inhibitor (NNRTI), and tenofovir (Viread, Gilead Sciences), and emtricitabine (Emtriva, Gilead Sciences), both nucleoside reverse transcriptase inhibitors (NRTIs).
Approval of the combination drug was based on previously conducted phase 3 randomized studies (ECHO and THRIVE) of rilpivirine, on which approval of that drug was based. No new studies were conducted for approval of Complera.
A bioequivalence study demonstrated that the triple-drug tablet achieved the same blood levels as each of the drugs administered individually.
The recommended dose of Complera is 1 tablet, containing emtricitabine 200 mg, rilpivirine 25 mg, and tenofovir 300 mg, once daily, to be taken with food.
FDA issued the following cautions in announcing the drug's approval:
  • More patients with HIV-1 RNA levels greater than 100,000 copies/mL at the start of therapy experienced virologic failure compared with subjects with lower HIV-1 RNA levels at the start of therapy with rilpivirine.
  • The virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the NNRTI class compared with efavirenz.
  • More subjects treated with rilpivirine developed lamivudine/emtricitabine-associated resistance compared with efavirenz.
Emtricitabine/rilpivirine/tenofovir DF is contraindicated in patients taking the following drugs:
  • the anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, and phenytoin
  • the antimycobacterials rifabutin, rifampin, and rifapentine
  • proton pump inhibitors, such as esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole
  • more than a single dose of systemic dexamethasone
  • St. John's wort
These drugs may cause significant decreases in rilpivirine plasma concentrations and may result in a loss of virologic response and possible resistance to rilpivirine or to all NNRTIs.
Labeling information will be posted soon on Drugs@FDA. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm

AVOID MULTIVESSEL PCI IN STEMI

August 5, 2011 (Groningen, the Netherlands and Tel Aviv, Israel) Two new studies published this week confirm clinical recommendations that a deferred angioplasty strategy of nonculprit lesions should remain the standard interventional approach in patients with ST-segment elevation MI (STEMI) undergoing primary PCI [1,2].
In the first study, an analysis of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS AMI) study, investigators, led by Dr Ron Kornowski (Tel Aviv University, Israel), observed significantly higher one-year mortality and stent-thrombosis rates among patients undergoing multivessel PCI compared with individuals undergoing staged PCI.
In the second study, a meta-analysis that included 18 studies and more than 40 000 patients, the investigators report that multivessel PCI was associated with the highest rates of death in short- and long-term follow-up when compared with culprit-lesion PCI and staged PCI.
Dr Pieter Vlaar (University Medical Center, Groningen, the Netherlands), the lead researcher of the meta-analysis, told heartwire that the results support current guidelines discouraging multivessel primary PCI for STEMI patients. That said, the guidelines are not based on large randomized controlled clinical trials, and this had led to some confusion and variability across different centers. Even at their institution, Vlaar said clinicians differ in their opinions about whether nonculprit lesions should be treated during the initial intervention. However, these new data suggest that when significant nonculprit lesions are suitable for PCI, "they should be treated only during staged interventions."
Both studies, as well as an accompanying editorial [3], are published in the August 9, 2011 issue of the Journal of the American College of Cardiology.
HORIZONS-AMI and the Meta-Analysis
In the meta-analysis, Vlaar and colleagues included data from four prospective and 14 retrospective studies involving 40 280 patients with multivessel disease undergoing primary PCI for STEMI. Three treatment strategies were compared:
PCI of the culprit vessel only.
Multivessel PCI, defined as PCI of the culprit vessel as well as one or more nonculprit vessel lesions.
Staged PCI, defined as PCI confined to the culprit vessel only, with one or more nonculprit lesions treated in staged interventions.
Compared with the staged-PCI strategy, PCI of the culprit lesion only and multivessel PCI were associated with a significant three- and fivefold increased risk of in-hospital/30-day mortality, respectively. In addition, 30-day mortality was significantly lower in patients treated with culprit PCI compared with multivessel PCI (odds ratio 0.66; 95% CI 0.48–0.89). Regarding long-term mortality, multivessel PCI was associated with a 60% increased risk of long-term mortality compared with culprit PCI, as well as a significantly greater risk compared with staged PCI.
In the HORIZONS-AMI study, the investigators compared primary PCI of the culprit and nonculprit lesions with patients who underwent PCI of the culprit lesions only and those who underwent staged PCI of the nonculprit lesion at a later date. Of the 3602 patients enrolled in the trial, 668 underwent PCI of the culprit and nonculprit lesions for multivessel disease, of whom 275 underwent a single PCI strategy and 393 underwent staged PCI.
At one year, patients who underwent single PCI had a mortality rate of 9.2% compared with 2.3% in patients who underwent staged PCI. In addition, single PCI was associated with significantly higher rates of cardiac mortality compared with staged PCI (6.2% vs 2.0%, respectively) and higher rates of definite/probable stent thrombosis (5.7% vs 2.3%, respectively).
In their paper, Kornowski and colleagues, including senior investigator Dr Gregg Stone (Columbia University, New York), state that a "deferred angioplasty strategy of nonculprit lesions should remain the standard approach in patients with STEMI undergoing primary PCI, as multivessel PCI may be associated with a greater hazard of mortality and stent thrombosis."
Some Unanswered Questions
Commenting on the findings for heartwire , Dr David Kandzari (Piedmont Heart Institute, Atlanta, GA) said, "Both papers provide welcome information to clinicians," especially since there are few randomized trials to provide sufficient information to guide treatment decisions. Most of the clinical recommendations are based on some clinical evidence, including cohort and retrospective studies, but they are largely the opinion of interventional experts.
In the US, the American College of Cardiology/American Heart Association guidelines state definitively that PCI "should not be performed in a noninfarct artery at the time of primary PCI in patients without hemodynamic compromise." The class-III (harm)/level-of-evidence B recommendation differs slightly from the European Society of Cardiology/European Association for Cardiothoracic Surgery guidelines, which are slightly more lenient. The European guidelines state that with the exception of cardiogenic shock, PCI for STEMI should be limited to the culprit lesion (class IIa, level of evidence B).
To heartwire , Kandzari explained that treating other lesions in patients with cardiogenic shock remains a "bit of a gray area" in the US. Although the guidelines explicitly state not to perform PCI of the nonculprit lesions, some clinicians will treat other stenoses in cardiogenic-shock patients in an attempt to provide as much flow as possible. That said, there is a discrepancy between the number of clinicians performing multivessel PCI and rates of cardiogenic shock. Dr John Bittl (Ocala Heart Institute, FL), who wrote an editorial accompanying the published studies, observed a similar discrepancy. For example, in HORIZONS-AMI, 18.5% of patients underwent multivessel PCI, but only 1.5% had cardiogenic shock. In the New York State registry, 12.5% of patients were treated with multivessel PCI, but only 4.4% met the definition of hemodynamic compromise.
Kandzari said he would like to know the reasons that the clinicians performed multivessel PCI in these STEMI patients, noting that in some instances it is difficult to determine what the culprit lesion is in acute MI. Some centers might not perform left and right coronary angiography before revascularizing the patient, and without assessment of the entire coronary anatomy, it is possible, although rare, to treat the wrong lesion. Some patients might not show any improvement following culprit PCI and as a result will undergo treatment of other lesions, he said.
In his editorial, Bittl made similar statements, noting that "no single approach is applicable to the myriad presentations of STEMI." He also noted that multivessel PCI might be necessary in the cases where patients do not show improvement following primary PCI of the culprit lesion. He added that patients with severe multivessel disease might require follow-up angiography and that fractional flow reserve (FFR) can be considered during the acute phase, but the "results should be used whenever possible to support a decision for staged PCI."
To heartwire , Vlaar said the benefit of staging patients is that angiograms can be discussed with a joint heart team and additional noninvasive ischemia tests and FFR can be performed before deciding to perform additional revascularizations.
Kandzari told heartwire that there still remain some questions regarding staged PCI in STEMI patients. For example, Kandzari said the optimal time for the second PCI is unknown. In the US, revascularization is driven by reimbursement issues, with physicians not compensated for staged PCI performed within 30 days of PCI for acute MI, so most clinicians are reluctant to treat other vessels even when the patient is in the hospital.
"Financial issues aside, we still don't know if it's better to treat the nonculprit lesions when the patient is still in the hospital, two weeks after the primary PCI, or four weeks after primary PCI," said Kandzari.

THIS IS NOT ABOUT MEDICINE-IT IS PURE BUSINESS

August 5, 2011 — Genentech has a new proposal for keeping its licensed indication for bevacizumab (Avastin) in breast cancer.
The US Food and Drug Administration (FDA) is in the process of revoking the license for this indication. A final decision on the issue is awaited from the FDA commissioner, but no date has been set.
The manufacturer has appealed the FDA move to revoke the license, but after the recent 2-day meeting, during which the company laid out all of its arguments, the FDA Oncology Drugs Advisory Committee voted unanimously against allowing the breast cancer indication to remain.
The new proposal appears to be a direct response to many of the concerns that were raised at that hearing. In what the company has described as a "middle-ground" proposal for keeping the indication, it has filed a posthearing summary, submitted to the FDA under Docket No. FDA-2010-N-0621.
"Two facts cannot be disputed in the wake of the hearing to withdraw [bevacizumab's] breast cancer indication," the company concludes in that document. "The approved treatment options for patients with metastatic disease are extremely limited, particularly for patients who face aggressive disease, and [bevacizumab] in combination with weekly paclitaxel indisputably has an effect on this form of breast cancer."
"These facts drive Genentech's proposal to retain accelerated approval of [bevacizumab] plus paclitaxel, subject to a confirmatory study and with revised labeling and risk communications that respond directly to the views" and concerns that have been expressed by the FDA, the company notes.
The manufacturer has proposed new labeling for the drug, with highlighted changes. In it, bevacizumab retains its indication for metastatic breast cancer, but the treatment is restricted to women with aggressive disease and the fewest treatment options (e.g., patients with aggressive hormone-receptor-positive breast cancer or triple-negative disease). In addition, the labeling would restrict bevacizumab to use with paclitaxel (as in the current indication, based on the best clinical trial data available), and would provide information about the "differing effects seen with other chemotherapies" (for which the clinical trial data are not as good). It would also contain "important safety considerations, including serious side effects," according to the company.
The proposal also suggests that this indication would be covered by a Risk Evaluation and Mitigation Strategy, which would involve the distribution of a medication guide to every physician and patient considering this treatment option.